Cargando…
Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
SIMPLE SUMMARY: Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its current applications include the first-line setting, second-line setting, as well as the adjuvant setting. Although it represents a milestone in the context of targeted therapy, inevitably all tumors develop an...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027936/ https://www.ncbi.nlm.nih.gov/pubmed/35454838 http://dx.doi.org/10.3390/cancers14081931 |
_version_ | 1784691491362308096 |
---|---|
author | Ríos-Hoyo, Alejandro Moliner, Laura Arriola, Edurne |
author_facet | Ríos-Hoyo, Alejandro Moliner, Laura Arriola, Edurne |
author_sort | Ríos-Hoyo, Alejandro |
collection | PubMed |
description | SIMPLE SUMMARY: Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its current applications include the first-line setting, second-line setting, as well as the adjuvant setting. Although it represents a milestone in the context of targeted therapy, inevitably all tumors develop an acquired resistance, some mechanisms involve EGFR, others do so through alternative pathways leading to a bypass in osimertinib inhibition. It is key to understand these acquired mechanisms of resistance, both in the clinical setting, as well as in preclinical models, in order to develop and contribute to the identification of possible therapeutic strategies to overcome this acquired resistance. ABSTRACT: EGFR-mutated tumors represent a significant percentage of non-small cell lung cancer. Despite the increasing use of osimertinib, a treatment that has demonstrated an outstanding clinical benefit with a tolerable toxicity profile, EGFR tumors eventually acquire mechanisms of resistance. In the last years, multiple mechanisms of resistance have been identified; however, after progressing on osimertinib, treatment options remain bleak. In this review, we cover the most frequent alterations and potential therapeutic strategies to overcome them. |
format | Online Article Text |
id | pubmed-9027936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90279362022-04-23 Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge Ríos-Hoyo, Alejandro Moliner, Laura Arriola, Edurne Cancers (Basel) Review SIMPLE SUMMARY: Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its current applications include the first-line setting, second-line setting, as well as the adjuvant setting. Although it represents a milestone in the context of targeted therapy, inevitably all tumors develop an acquired resistance, some mechanisms involve EGFR, others do so through alternative pathways leading to a bypass in osimertinib inhibition. It is key to understand these acquired mechanisms of resistance, both in the clinical setting, as well as in preclinical models, in order to develop and contribute to the identification of possible therapeutic strategies to overcome this acquired resistance. ABSTRACT: EGFR-mutated tumors represent a significant percentage of non-small cell lung cancer. Despite the increasing use of osimertinib, a treatment that has demonstrated an outstanding clinical benefit with a tolerable toxicity profile, EGFR tumors eventually acquire mechanisms of resistance. In the last years, multiple mechanisms of resistance have been identified; however, after progressing on osimertinib, treatment options remain bleak. In this review, we cover the most frequent alterations and potential therapeutic strategies to overcome them. MDPI 2022-04-12 /pmc/articles/PMC9027936/ /pubmed/35454838 http://dx.doi.org/10.3390/cancers14081931 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ríos-Hoyo, Alejandro Moliner, Laura Arriola, Edurne Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge |
title | Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge |
title_full | Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge |
title_fullStr | Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge |
title_full_unstemmed | Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge |
title_short | Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge |
title_sort | acquired mechanisms of resistance to osimertinib—the next challenge |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027936/ https://www.ncbi.nlm.nih.gov/pubmed/35454838 http://dx.doi.org/10.3390/cancers14081931 |
work_keys_str_mv | AT rioshoyoalejandro acquiredmechanismsofresistancetoosimertinibthenextchallenge AT molinerlaura acquiredmechanismsofresistancetoosimertinibthenextchallenge AT arriolaedurne acquiredmechanismsofresistancetoosimertinibthenextchallenge |